ArticlePPAR research2009
PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.
Article in PPAR research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationPooled it
- Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-γ agonist, after a single oral administration in healthy female subjects.Clinical drug investigation · 2014Trial
- Sex-specific role of microglia in ΔNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Multi-omic analysis of the liver-breast axis reveals key hepatic mediators of breast cancer progression.Science China. Life sciences · 2026Review
- Asiatic acid mitigates testosterone-induced benign prostatic hyperplasia in rats via activation of PPAR-γ.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Nutritional, Nutraceutical, and Medicinal Potential ofFood science & nutrition · 2025Review
- Lipids associated with autophagy: mechanisms and therapeutic targets.Cell death discovery · 2024Review
- The role of silicon in drug discovery: a review.RSC medicinal chemistry · 2024Review
- Targeting lipid-sensing nuclear receptors PPAR (α, γ, β/δ): HTVS and molecular docking/dynamics analysis of pharmacological ligands as potential pan-PPAR agonists.Molecular diversity · 2024Article
- Multiple gene-drug prediction tool reveals Rosiglitazone based treatment pathway for non-segmental vitiligo.Inflammation · 2024Article
- In silico analysis of polyphenols modulate bovine PPARγ to increase milk fat synthesis in dairy cattle via the MAPK signaling pathways.Journal of animal science · 2024Article
- Extracting Potential New Targets for Treatment of Adenoid Cystic Carcinoma using Bioinformatic Methods.Iranian biomedical journal · 2023Article
- Gastrodin ameliorates cognitive dysfunction in diabetes by inhibiting PAK2 phosphorylation.Aging · 2023Article
- Single-cell transcriptomic profile of satellite glial cells in trigeminal ganglion.Frontiers in molecular neuroscience · 2023Article
- Identifying chemicals based on receptor binding/bioactivation/mechanistic explanation associated with potential to elicit hepatotoxicity and to support structure activity relationship-based read-across.Current research in toxicology · 2023Article
- SUMOylation Pattern Predicts Prognosis and Indicates Tumor Microenvironment Infiltration Characterization in Bladder Cancer.Frontiers in immunology · 2022Article
- Nephrotoxicity of perfluorooctane sulfonate (PFOS)-effect on transcription and epigenetic factors.Environmental epigenetics · 2022Article
- Nitro Fatty Acids (NOMolecules (Basel, Switzerland) · 2021Review
- Peroxisome Proliferator-Activated Receptor Gamma Pro12Ala/C161T Genotypes and Risky Haplotype Altering Risk of Breast Cancer: A Turkish Case-Control Study.Biochemical genetics · 2021Article
- Cheonggukjang-Specific Component 1,3-Diphenyl-2-Propanone as a Novel PPARα/γ Dual Agonist: An In Vitro and In Silico Study.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is now well established that the development and progression of a variety of human malignancies are associated with dysregulated activity of the insulin-like growth factor (IGF) system. In this regard, promising drugs have been developed to target the IGF-I receptor or its ligands. These therapies are limited by the development of insulin resistance and compensatory hyperinsulinemia, which in turn, may stimulate cancer growth. Novel therapeutic approaches are, therefore, required. Synthetic PPAR-γ agonists, such as thiazolidinediones (TZDs), are drugs universally used as antidiabetic agents in patients with type 2 diabetes. In addition of acting as insulin sensitizers, PPAR-γ agonists mediate in vitro and in vivo pleiotropic anticancer effects. At least some of these effects appear to be linked with the downregulation of the IGF system, which is induced by the cross-talk of PPAR-γ agonists with multiple components of the IGF system signaling. As hyperinsulinemia is an emerging cancer risk factor, the insulin lowering action of PPAR-γ agonists may be expected to be also beneficial to reduce cancer development and/or progression. In light of these evidences, TZDs or other PPAR-γ agonists may be exploited in those tumors "addicted" to the IGF signaling and/or in tumors occurring in hyperinsulinemic patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.